262 related articles for article (PubMed ID: 21828189)
41. Optimizing MRI scan time in the computation of pharmacokinetic parameters (K(trans) ) in breast cancer diagnosis.
Jena A; Mehta SB; Taneja S
J Magn Reson Imaging; 2013 Sep; 38(3):573-9. PubMed ID: 23349046
[TBL] [Abstract][Full Text] [Related]
42. Diagnostic Performance of Dynamic Contrast-Enhanced 3T MR Imaging for Characterization of Orbital Lesions: Validation in a Large Prospective Study.
O'Shaughnessy E; Cossec CL; Mambour N; Lecoeuvre A; Savatovsky J; Zmuda M; Duron L; Lecler A
AJNR Am J Neuroradiol; 2024 Mar; 45(3):342-350. PubMed ID: 38453407
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of quantitative parametric analysis for characterization of breast lesions in contrast-enhanced MR mammography.
Hauth EA; Jaeger H; Maderwald S; Stockamp C; Mühler A; Kimmig R; Forsting M
Eur Radiol; 2006 Dec; 16(12):2834-41. PubMed ID: 16896702
[TBL] [Abstract][Full Text] [Related]
44. Solid pancreatic lesions: characterization by using timing bolus dynamic contrast-enhanced MR imaging assessment--a preliminary study.
Kim JH; Lee JM; Park JH; Kim SC; Joo I; Han JK; Choi BI
Radiology; 2013 Jan; 266(1):185-96. PubMed ID: 23192779
[TBL] [Abstract][Full Text] [Related]
45. High temporal resolution 3D gadolinium-enhanced dynamic MR imaging of renal tumors with pharmacokinetic modeling: preliminary observations.
Chandarana H; Amarosa A; Huang WC; Kang SK; Taneja S; Melamed J; Kim S
J Magn Reson Imaging; 2013 Oct; 38(4):802-8. PubMed ID: 23389833
[TBL] [Abstract][Full Text] [Related]
46. Reproducibility of dynamic contrast-enhanced MR imaging. Part I. Perfusion characteristics in the female pelvis by using multiple computer-aided diagnosis perfusion analysis solutions.
Heye T; Davenport MS; Horvath JJ; Feuerlein S; Breault SR; Bashir MR; Merkle EM; Boll DT
Radiology; 2013 Mar; 266(3):801-11. PubMed ID: 23220897
[TBL] [Abstract][Full Text] [Related]
47. Contrast-enhanced MR mammography for evaluation of the contralateral breast in patients with diagnosed unilateral breast cancer or high-risk lesions.
Pediconi F; Catalano C; Roselli A; Padula S; Altomari F; Moriconi E; Pronio AM; Kirchin MA; Passariello R
Radiology; 2007 Jun; 243(3):670-80. PubMed ID: 17446524
[TBL] [Abstract][Full Text] [Related]
48. Improving the Accuracy of Computer-aided Diagnosis for Breast MR Imaging by Differentiating between Mass and Nonmass Lesions.
Gallego-Ortiz C; Martel AL
Radiology; 2016 Mar; 278(3):679-88. PubMed ID: 26383229
[TBL] [Abstract][Full Text] [Related]
49. Comparison of nonenhanced MR angiographic subtraction techniques for infragenual arteries at 1.5 T: a preliminary study.
Lim RP; Fan Z; Chatterji M; Baadh A; Atanasova IP; Storey P; Kim DC; Kim S; Hodnett PA; Ahmad A; Stoffel DR; Babb JS; Adelman MA; Xu J; Li D; Lee VS
Radiology; 2013 Apr; 267(1):293-304. PubMed ID: 23297320
[TBL] [Abstract][Full Text] [Related]
50. Use of dynamic contrast-enhanced MR imaging to predict survival in patients with primary breast cancer undergoing neoadjuvant chemotherapy.
Li SP; Makris A; Beresford MJ; Taylor NJ; Ah-See ML; Stirling JJ; d'Arcy JA; Collins DJ; Kozarski R; Padhani AR
Radiology; 2011 Jul; 260(1):68-78. PubMed ID: 21502383
[TBL] [Abstract][Full Text] [Related]
51. Histogram analysis of whole-lesion enhancement in differentiating clear cell from papillary subtype of renal cell cancer.
Chandarana H; Rosenkrantz AB; Mussi TC; Kim S; Ahmad AA; Raj SD; McMenamy J; Melamed J; Babb JS; Kiefer B; Kiraly AP
Radiology; 2012 Dec; 265(3):790-8. PubMed ID: 23175544
[TBL] [Abstract][Full Text] [Related]
52. Use of dynamic phase subtraction (DPS) map in dynamic contrast-enhanced MRI of the breast.
Ogura A; Hayakawa K; Yoshida S; Maeda F; Saeki F; Syukutani A
J Comput Assist Tomogr; 2011; 35(6):749-52. PubMed ID: 22082548
[TBL] [Abstract][Full Text] [Related]
53. Soft-tissue tumors: value of static and dynamic gadopentetate dimeglumine-enhanced MR imaging in prediction of malignancy.
van Rijswijk CS; Geirnaerdt MJ; Hogendoorn PC; Taminiau AH; van Coevorden F; Zwinderman AH; Pope TL; Bloem JL
Radiology; 2004 Nov; 233(2):493-502. PubMed ID: 15459325
[TBL] [Abstract][Full Text] [Related]
54. Comparing perfusion metrics obtained from a single compartment versus pharmacokinetic modeling methods using dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade.
Law M; Young R; Babb J; Rad M; Sasaki T; Zagzag D; Johnson G
AJNR Am J Neuroradiol; 2006 Oct; 27(9):1975-82. PubMed ID: 17032878
[TBL] [Abstract][Full Text] [Related]
55. Evaluation of the three-time-point method for diagnosis of breast lesions in contrast-enhanced MR mammography.
Hauth EA; Stockamp C; Maderwald S; Mühler A; Kimmig R; Jaeger H; Barkhausen J; Forsting M
Clin Imaging; 2006; 30(3):160-5. PubMed ID: 16632149
[TBL] [Abstract][Full Text] [Related]
56. Intra-individual comparison of different gadolinium-based contrast agents in the quantitative evaluation of C6 glioma with dynamic contrast-enhanced magnetic resonance imaging.
Li Y; Liu G; Lou X; Chen Z; Ma L
Sci China Life Sci; 2017 Jan; 60(1):11-15. PubMed ID: 28078511
[TBL] [Abstract][Full Text] [Related]
57. The magnetic resonance shutter speed discriminates vascular properties of malignant and benign breast tumors in vivo.
Huang W; Li X; Morris EA; Tudorica LA; Seshan VE; Rooney WD; Tagge I; Wang Y; Xu J; Springer CS
Proc Natl Acad Sci U S A; 2008 Nov; 105(46):17943-8. PubMed ID: 19004780
[TBL] [Abstract][Full Text] [Related]
58. Dynamic MR mammography: a technique for potentially reducing the biopsy rate for benign breast disease.
Turkat TJ; Klein BD; Polan RL; Richman RH
J Magn Reson Imaging; 1994; 4(4):563-8. PubMed ID: 7949682
[TBL] [Abstract][Full Text] [Related]
59. Diagnostic Accuracy of Preoperative Gadoxetic Acid-enhanced 3-T MR Imaging for Malignant Liver Lesions by Using Ex Vivo MR Imaging-matched Pathologic Findings as the Reference Standard.
Costa EA; Cunha GM; Smorodinsky E; Cruite I; Tang A; Marks RM; Clark L; Wolfson T; Gamst A; Sicklick JK; Hemming A; Peterson MR; Middleton MS; Sirlin CB
Radiology; 2015 Sep; 276(3):775-86. PubMed ID: 25875972
[TBL] [Abstract][Full Text] [Related]
60. Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results.
Padhani AR; Hayes C; Assersohn L; Powles T; Makris A; Suckling J; Leach MO; Husband JE
Radiology; 2006 May; 239(2):361-74. PubMed ID: 16543585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
